Jump to main content
Jump to site search


Towards rational design of RAD51-targeting prodrugs: platinumIV–artesunate conjugates with enhanced cytotoxicity against BRCA-proficient ovarian and breast cancer cells

Author affiliations

Abstract

Two PtIV–artesunate anticancer prodrugs that target RAD51, a crucial protein in homologous recombination mediating the sensitivity of cancer cells to DNA-damaging agents, were designed; their cytotoxicities against BRCA-proficient ovarian and breast cancer cells are significantly higher than those of cisplatin.

Graphical abstract: Towards rational design of RAD51-targeting prodrugs: platinumIV–artesunate conjugates with enhanced cytotoxicity against BRCA-proficient ovarian and breast cancer cells

Back to tab navigation

Supplementary files

Publication details

The article was received on 13 Aug 2018, accepted on 11 Sep 2018 and first published on 11 Sep 2018


Article type: Communication
DOI: 10.1039/C8CC06576D
Citation: Chem. Commun., 2018, Advance Article
  •   Request permissions

    Towards rational design of RAD51-targeting prodrugs: platinumIV–artesunate conjugates with enhanced cytotoxicity against BRCA-proficient ovarian and breast cancer cells

    S. Zhang, H. Yuan, Y. Guo, K. Wang, X. Wang and Z. Guo, Chem. Commun., 2018, Advance Article , DOI: 10.1039/C8CC06576D

Search articles by author

Spotlight

Advertisements